Tarsus Pharmaceuticals Inc (TARS) returns
Tarsus Pharmaceuticals returns over 5 years
$1,000 invested in Tarsus Pharmaceuticals five years ago was worth $2,696 at the close on October 30, 2026, with dividends reinvested: an average return of 21.9% a year. The same $1,000 in the S&P 500 (SPY) became $1,760.
Total return by period
| Period | Total return | A year, on average | $1,000 became | S&P 500 (SPY) |
|---|---|---|---|---|
| 1 month | -4.8% | — | $952.17 | -0.9% |
| 3 months | +25.7% | — | $1,257 | +2.1% |
| Year to date | -8.6% | — | $914.14 | +11.7% |
| 1 year | +8.5% | — | $1,085 | +12.4% |
| 3 years | +430.1% | +74.4% | $5,301 | +88.5% |
| 5 years | +169.6% | +21.9% | $2,696 | +76.0% |
Tarsus Pharmaceuticals return by calendar year
| Year | TARS | S&P 500 (SPY) | Difference |
|---|---|---|---|
| 2026 to date | -8.6% | +11.7% | -20.3% |
| 2025 | +47.9% | +17.7% | +30.2% |
| 2024 | +173.4% | +24.9% | +148.5% |
| 2023 | +38.1% | +26.2% | +11.9% |
| 2022 | -34.8% | -18.2% | -16.7% |
| 2021 | -45.6% | +28.7% | -74.3% |
Past returns do not predict future returns. Returns are computed from our daily closes, adjusted for splits and with dividends reinvested on their ex-dates; taxes and trading costs are left out.
See also: TARS financials
No forecast, no recommendation. This page describes Tarsus Pharmaceuticals Inc from published data; it is not advice to buy, sell or hold any security.
Figures as of the close on Oct 30, 2026 unless a row says otherwise. Prices are split adjusted; returns include dividends reinvested. Data may be delayed. See the disclaimer and how TrendArc works.